Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
CDKN2A and breast cancer are reported together in 6 articles.
Gene
CDKN2A
- HGNC
- HGNC:1787
48articles
48mentions
0variants with confirmed gene link
Most co-reported phenotypes (articles)
Phenotype
Breast cancer
1,211articles
1,211mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
6 records shown · first 60Novel 2 Gene Signatures Associated With Breast Cancer Proliferation: Insights From Predictive Differential Gene Expression Analysis.
PMID 38104894 | DOI 10.1016/j.modpat.2023.100403 · Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024 · 11 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CDKN2A | “Ten hub genes (ORC6, SKP2, SMC1B, CDKN2A, CDC25B, E2F1, E2F2, ORC1, PTTG1, and CDC25A) were identified using CytoHubba a Cytoscape plugin.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Novel 2 Gene Signatures Associated With Breast Cancer Proliferation: Insights From Predictive Differential Gene Expression Analysis.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | ORC6 | “Ten hub genes (ORC6, SKP2, SMC1B, CDKN2A, CDC25B, E2F1, E2F2, ORC1, PTTG1, and CDC25A) were identified using CytoHubba a Cytoscape plugin.” | 0.98 | hgnc_dict_v1 |
| gene | SKP2 | “Ten hub genes (ORC6, SKP2, SMC1B, CDKN2A, CDC25B, E2F1, E2F2, ORC1, PTTG1, and CDC25A) were identified using CytoHubba a Cytoscape plugin.” | 0.98 | hgnc_dict_v1 |
A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy.
PMID 36964435 | DOI 10.1007/s00280-023-04523-w · Cancer chemotherapy and pharmacology · 2023 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CDKN2A | “Gene expression sets of two independent NAC-treated breast cancer samples showed consistent changes in the expression levels of LMNB1, MKI67 and CDKN2A.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | LMNB1 | “Gene expression sets of two independent NAC-treated breast cancer samples showed consistent changes in the expression levels of LMNB1, MKI67 and CDKN2A.” | 0.98 | hgnc_dict_v1 |
| gene | MKI67 | “Gene expression sets of two independent NAC-treated breast cancer samples showed consistent changes in the expression levels of LMNB1, MKI67 and CDKN2A.” | 0.98 | hgnc_dict_v1 |
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
PMID 30355675 | PMCID PMC6359977 | DOI 10.1158/1541-7786.MCR-18-0946 · Molecular cancer research : MCR · 2019 · 9 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CDKN2A | “Other frequent amplifications included ERBB2, GRB7, and cell-cycle pathway members CCND1 and CDK4/6, which showed mutually exclusivity with deletions of CDKN2A, CDKN2B, and CDKN1B.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | ESR1 | “Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.” | 0.98 | hgnc_dict_v1 |
| gene | ERBB2 | “Other frequent amplifications included ERBB2, GRB7, and cell-cycle pathway members CCND1 and CDK4/6, which showed mutually exclusivity with deletions of CDKN2A, CDKN2B, and CDKN1B.” | 0.98 | hgnc_dict_v1 |
Zinc enhances CDKN2A, pRb1 expression and regulates functional apoptosis via upregulation of p53 and p21 expression in human breast cancer MCF-7 cell.
PMID 27567443 | DOI 10.1016/j.etap.2016.08.002 · Environmental toxicology and pharmacology · 2016 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CDKN2A | “Zinc enhances CDKN2A, pRb1 expression and regulates functional apoptosis via upregulation of p53 and p21 expression in human breast cancer MCF-7 cell.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Zinc enhances CDKN2A, pRb1 expression and regulates functional apoptosis via upregulation of p53 and p21 expression in human breast cancer MCF-7 cell.” | 0.98 | phenotype_alias_lexicon_v2 |
miR-146b-5p mediates p16-dependent repression of IL-6 and suppresses paracrine procarcinogenic effects of breast stromal fibroblasts.
PMID 26338965 | PMCID PMC4745778 | DOI 10.18632/oncotarget.4933 · Oncotarget · 2015 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CDKN2A | “Interestingly, treatment of active breast stromal fibroblasts with curcumin increased the level of the p16(INK4A) coding CDKN2A mRNA and miR-146b-5p and suppressed IL-6, which confirms the repressive effect of these two tumor suppressor molecules on IL-6, and shows the possible "normalization" of cancer-related active fibroblasts.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Increasing evidence support the critical roles of active stromal fibroblasts in breast cancer development and spread.” | 0.98 | phenotype_alias_lexicon_v2 |
RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency.
PMID 21868547 · Anticancer research · 2011 · 11 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CDKN2A | “In an effort to understand the molecular signature of BC in the Saudi population, we undertook this study to profile the methylation events in a series of key genes including Ras association (RalGDS/AF-6) domain family member 1 isoform a (RASSF1A), hypermethylated in cancer 1 (HIC1), cyclin-dependent kinase inhibitor 2A (CDKN2A), retinoic acid receptor beta (RARB2), estrogen receptor 1 (ESR1), progesterone receptor (PGR), paired-like homeodomain 2 (PITX2), secreted frizzled-related protein 1 (SFRP1), myogenic differentiation 1 (MYOD1), and slit homolog 2 (SLIT2), using MethyLight analysis in archival tumour samples.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | HIC1 | “In an effort to understand the molecular signature of BC in the Saudi population, we undertook this study to profile the methylation events in a series of key genes including Ras association (RalGDS/AF-6) domain family member 1 isoform a (RASSF1A), hypermethylated in cancer 1 (HIC1), cyclin-dependent kinase inhibitor 2A (CDKN2A), retinoic acid receptor beta (RARB2), estrogen receptor 1 (ESR1), progesterone receptor (PGR), paired-like homeodomain 2 (PITX2), secreted frizzled-related protein 1 (SFRP1), myogenic differentiation 1 (MYOD1), and slit homolog 2 (SLIT2), using MethyLight analysis in archival tumour samples.” | 0.98 | hgnc_dict_v1 |
| gene | ESR1 | “In an effort to understand the molecular signature of BC in the Saudi population, we undertook this study to profile the methylation events in a series of key genes including Ras association (RalGDS/AF-6) domain family member 1 isoform a (RASSF1A), hypermethylated in cancer 1 (HIC1), cyclin-dependent kinase inhibitor 2A (CDKN2A), retinoic acid receptor beta (RARB2), estrogen receptor 1 (ESR1), progesterone receptor (PGR), paired-like homeodomain 2 (PITX2), secreted frizzled-related protein 1 (SFRP1), myogenic differentiation 1 (MYOD1), and slit homolog 2 (SLIT2), using MethyLight analysis in archival tumour samples.” | 0.98 | hgnc_dict_v1 |